CureVac withdraws authorisation application for COVID-19 vaccine

Vaccine candidate CVnCoV no longer in rolling review procedure


CureVac Swiss AG has withdrawn its application to Swissmedic for the authorisation of its vaccine candidate CVnCoV.

In a press release dated 12 October 2021, Tübingen-based biopharma company CureVac said that it would no longer be developing its first-generation COVID-19 vaccine to market readiness, and would instead be focusing on a second-generation COVID-19 vaccine.

Thus on 18 October 2021 CureVac Swiss AG also withdrew the application for authorisation that it had submitted to Swissmedic, the Swiss Agency for Therapeutic Products, in April 2021.

Address for enquiries

Media Unit

+41 58 462 02 76